Literature DB >> 16932592

Methylprednisolone and other confounders to spinal cord injury clinical trials.

Marca L Sipski1, Damien D Pearse.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16932592     DOI: 10.1038/ncpneuro0221

Source DB:  PubMed          Journal:  Nat Clin Pract Neurol        ISSN: 1745-834X


× No keyword cloud information.
  5 in total

1.  Acute molecular perturbation of inducible nitric oxide synthase with an antisense approach enhances neuronal preservation and functional recovery after contusive spinal cord injury.

Authors:  Dominic M Maggio; Katina Chatzipanteli; Neil Masters; Samik P Patel; W Dalton Dietrich; Damien D Pearse
Journal:  J Neurotrauma       Date:  2012-08-10       Impact factor: 5.269

2.  Dose and chemical modification considerations for continuous cyclic AMP analog delivery to the injured CNS.

Authors:  Karim Fouad; Mousumi Ghosh; Romana Vavrek; Arthur D Tse; Damien D Pearse
Journal:  J Neurotrauma       Date:  2009-05       Impact factor: 5.269

3.  The therapeutic profile of rolipram, PDE target and mechanism of action as a neuroprotectant following spinal cord injury.

Authors:  Sandra Marie Schaal; Maneesh Sen Garg; Mousumi Ghosh; Lilie Lovera; Michael Lopez; Monal Patel; Jack Louro; Samik Patel; Luis Tuesta; Wai-Man Chan; Damien Daniel Pearse
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

Review 4.  Fundamentals of clinical outcomes assessment for spinal disorders: study designs, methodologies, and analyses.

Authors:  Patrick Vavken; Anne Kathleen B Ganal-Antonio; Francis H Shen; Jens R Chapman; Dino Samartzis
Journal:  Global Spine J       Date:  2015-03-12

5.  Bridging the lesion-engineering a permissive substrate for nerve regeneration.

Authors:  Liliana R Pires; Ana P Pêgo
Journal:  Regen Biomater       Date:  2015-08-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.